Skip to main content
. 2020 Jul 15;1(4):100074. doi: 10.1016/j.jtocrr.2020.100074

Figure 3.

Figure 3

(A) The proportion of patients who achieved a complete or partial response to immunotherapy in the irAEs group and no-irAEs group. (B) Waterfall plot illustrating the percentage change of tumor target lesions compared with baseline in patients with assessable target lesions. (C) Swimmer plot illustrating the duration of PFS among the 24 patients who responded to immunotherapy. The time to response and the time to irAE onset are also illustrated. irAE, immune-related adverse event; PFS, progression-free survival.